enzastaurin   Click here for help

GtoPdb Ligand ID: 5693

Synonyms: LY-317615 | LY317615
Compound class: Synthetic organic
Comment: Enzastaurin is a selective inhibitor of protein kinase Cβ [2-3]. Note that reported affinity values may have been generated using the hydrochloride salt (PubChem CID 176166).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 72.16
Molecular weight 515.23
XLogP 4.73
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C1NC(=O)C(=C1c1cn(c2c1cccc2)C1CCN(CC1)Cc1ccccn1)c1cn(c2c1cccc2)C
Isomeric SMILES O=C1NC(=O)C(=C1c1cn(c2c1cccc2)C1CCN(CC1)Cc1ccccn1)c1cn(c2c1cccc2)C
InChI InChI=1S/C32H29N5O2/c1-35-19-25(23-9-2-4-11-27(23)35)29-30(32(39)34-31(29)38)26-20-37(28-12-5-3-10-24(26)28)22-13-16-36(17-14-22)18-21-8-6-7-15-33-21/h2-12,15,19-20,22H,13-14,16-18H2,1H3,(H,34,38,39)
No information available.
Summary of Clinical Use Click here for help
Enzastaurin is being evaluated for ability to reduce growth of malignant tumours. The most advanced studies are Phase 3. Click here to link to ClinicalTrials.gov's full list of enzastaurin studies.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Inhibition of PKCβ reduces downstream induction of vascular endothelial growth factor (VEGF)-stimulated neo-angiogenesis and may therefore reduce the vascularisation required for tumour growth.